Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Diabetes pioglitazone

Monitoring See Warnings. Perform periodic fasting blood glucose and HbAic measurements to monitor therapeutic response. Liver enzyme monitoring is recommended prior to initiation of therapy in all patients and periodically thereafter. Type 1 diabetes Pioglitazone and rosiglitazone are active only in the presence of... [Pg.330]

PPARy White adipose tissue, atherosclerotic lesions Insulin-sensitizing and glucoselowering re-directs TG from non-adipose tissues and visceral adipose depots for storage in subcutaneous adipose tissue slowed progression of atherosclerosis Fatty acids, eico-sanoids Th iazolid i ned iones pioglitazone (Actos ), rosiglita-zone (Avandia ) Type 2 diabetes, (insulin resistance, metabolic syndrome)... [Pg.945]

A.I. Vinik, P.M.M. Barlow, J. Ullal, C.M. Casellini, H.K. Parson, Pioglitazone treatment improves nit-rosative stress in type 2 diabetes. Diabetes Care 29, 869-876 (2006). [Pg.52]

A 60-year-old diabetic male is treated with pioglitazone What is the mechanism of action of pioglitazone ... [Pg.242]

Type 2 diabetes - As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of pioglitazone and metformin or whose diabetes is not adequately controlled with metformin alone, or for those patients who have initially responded to pioglitazone alone and require additional glycemic control. [Pg.333]

Sitagliptin is a selective dipeptidylpeptidase 4 (DPP-4) inhibitor which increases the active form of GLP-1 (glucagon-like-peptide-1) and GIP (glucose-dependent insulinotropic peptide). This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Adverse effects were as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for nausea and common cold-like symptoms. [Pg.397]

Rajagopalan R, Perez A, Ye Z, et. al. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 2004 21 259-271. [Pg.996]

Dormandy et al Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macroVascular Events) A randomized controlled trial. Lancet 2005,366 1279. [PMID 16214598]... [Pg.951]

Goldberg RB et al A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes... [Pg.951]

Lincoff AM et al Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus (a meta-analysis of randomized trials). 2007 298 1180. [PMID 17848652]... [Pg.951]

The combination of metformin with various sulfonylurea derivatives has been extensively reviewed (15). When metformin or pioglitazone were added to sulfonylureas in patients with type 2 diabetes who were poorly controlled, those with reduced pancreatic beta cell function responded better to metformin, while those with greater insulin resistance responded better to pioglitazone (23). [Pg.369]

Nagasaka S, Aiso Y, Yoshiwaza K, Ishibashi S. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabetic Med 2004 21 136 1. [Pg.379]

In 244 patients with type 2 diabetes who took pioglitazone 30 or 45 mg/day for 20 weeks or 30 mg/day for 12 weeks and then 45 mg/day for 8 weeks, blood pressure, liver enzymes, and lipid profile improved and HbAlc fell by 1% (25). There was one serious adverse effect related to pioglitazone severe headache and severe weight gain in a patient taking 30 mg/day, which required drug withdrawal. [Pg.459]

It is possible that the combination of rosiglitazone with fenofibrate was responsible for the severe myopathy, although the possibility of a single drug cannot be excluded. Raised creatine kinase activity has been reported with troglitazone, and there has been a report of rhabdomyolysis in a patient with type 2 diabetes taking pioglitazone when fenofibrate was added. [Pg.462]

Thiazolidinediones cause recruitment and conversion of pre-adipocytes into adipocytes and are therefore adi-pogenic (75). In 18 patients without diabetes, mean age 46 years, who took pioglitazone 30 mg/day for 48 weeks for non-alcoholic steatohepatitis, there was a mean weight gain of 3.5 kg in 72% (76). Similarly, in 91 patients with type 2 diabetes who took pioglitazone 30 or 45 mg/day for... [Pg.463]

Insulin resistance in type 2 diabetes contributes to reduced efficacy of both endogenous and exogenous insulin. When metformin and pioglitazone were compared in patients who had not taken previous drug therapy, they were equally efficacious in glycemic control, but parameters of insulin sensitivity increased much more with pioglitazone (83). [Pg.463]

The authors of the second report speculated that this patient had pioglitazone-induced acute liver damage superimposed on chronic liver disease related to diabetes. [Pg.466]

Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001 23(ll) 1792-823. [Pg.469]

Gerber P, Liibben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure a randomized study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003 6 532-9. [Pg.469]

Schofl C, Liibben G. Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patents with type 2 diabetes mellitus in general practice. Clin Drug Invest 2003 23 725-34. [Pg.469]

Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RLThe Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000 23(11) 1605-11. [Pg.470]

Shimono D, Kuwamura N, Nakamura Y, Koshiyama H. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes. Diabetes Care 2001 24(5) 971. [Pg.470]

Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus a randomized, placebo-controlled study. Am J Med 2001 lll(l) 10-7. [Pg.470]

Javanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004 63 127-34. [Pg.470]

Jun JK, Gong WC, Mathur R. Effects of pioglitazone on diabetes related outcomes in Hispanic patients. Am J Health-Syst Pharm 2003 60 469-73. [Pg.471]

Igarashi M, Jimbu, Y, Hirato A, Yamaguchi H, Kato T, Tominaga M. Effect of pioglitazone on the plasma concentration of brain natriuretic peptide in patients with type 2 diabetes. Ther Res 2003 24 1873-81. [Pg.471]

Tan MH, Johns D, Strand J, Hlse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M, for the GLAC Study Group. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control and lipid profiles in patients with type 2 diabetes. Diabetic Med 2004 21 859-66. [Pg.471]

See other pages where Diabetes pioglitazone is mentioned: [Pg.122]    [Pg.122]    [Pg.41]    [Pg.69]    [Pg.73]    [Pg.944]    [Pg.503]    [Pg.46]    [Pg.507]    [Pg.542]    [Pg.65]    [Pg.354]    [Pg.757]    [Pg.225]    [Pg.944]    [Pg.948]    [Pg.915]    [Pg.461]    [Pg.463]   
See also in sourсe #XX -- [ Pg.202 ]



SEARCH



Pioglitazone diabetes treatment

© 2024 chempedia.info